Open date: April 6th, 2021
Next review date: Tuesday, Apr 20, 2021 at 11:59pm (Pacific Time)
Apply by this date to ensure full consideration by the committee.
Final date: Wednesday, Jun 30, 2021 at 11:59pm (Pacific Time)
Applications will continue to be accepted until this date, but those received after the review date will only be considered if the position has not yet been filled.
The Division of Infectious Diseases, in the Department of Medicine, David Geffen School of Medicine at UCLA is seeking to applicants for a full-time, Postdoctoral position 2-year funded position by NIH. The incumbent will conduct research in novel therapeutic approaches to treat viral infections including HIV and Covid-19. Preferred qualifications: Familiar with techniques such as multi-color flow cytometry, sterile technique for cell culture with BSL-2+ practices, ELISA, qRT-PCR, immunofluorescence, Western Blot and molecular biology techniques. Mouse experience is preferred but is not required. Experience in virology research is preferred but is not required. The candidate should be comfortable working with BSL2+ biospecimens including biospecimens (cells, plasma, tissues) from patients or mice with COVID-19 and/or HIV. A Ph.D. is required.
Overview: The pandemic COVID-19 emphasized the need to develop novel therapeutic strategies to combat morbidity and mortality from viral infections. The Kelesidis laboratory focuses on novel antioxidants that target increased bioactive lipids and altered mitochondria to attenuate increased systemic inflammation, immune dysfunction and end organ disease in chronic HIV infection. Importantly these antioxidants were also recently shown to attenuate SARS-CoV-2 viral replication and associated inflammatory responses in lung cells. The lab uses in vitro cell culture models, ex vivo models of atherogenesis and gut explants to dissect mechanisms how the cross talk between bioactive lipids, immune, endothelial and epithelial cells drive atherogenesis and how novel therapeutic agents attenuate aberrant proinflammatory cellular pathways. The lab also uses a preclinical humanized mouse model of chronic treated HIV infection to study in vivo how novel therapies attenuate end organ disease. Recent areas of research include studies of pathogenesis of COVID-19 using preclinical in vitro and animal models of SARS-CoV-2 infection.
The University of California is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age or protected veteran status. For the complete University of California nondiscrimination and affirmative action policy see: UC Nondiscrimination and Affirmative Action Policy.
Curriculum Vitae - Your most recently updated C.V.
Cover Letter (Optional)
Statement of Research (Optional)
Statement of Teaching (Optional)
Statement on Contributions to Equity, Diversity, and Inclusion - An EDI Statement describes a faculty candidate’s past, present, and future (planned) contributions to equity, diversity, and inclusion. To learn more about how UCLA thinks about contributions to equity, diversity, and inclusion, please review our Sample Guidance for Candidates and related EDI Statement FAQ document.
Misc / Additional (Optional)
- 0-3 required (contact information only)